2018 International Congress Archives - Page 52 of 177

Saccades in Parkinson’s disease: Hypometric, slow, or maladaptive?

L. Neilson, F. Ghasia, A. Shaikh (Cleveland, OH, USA)
Safety and efficacy of high definition tDCS for proprioception and balance in Parkinson’s disease: A pilot randomised trial

H. Teasdale, E. Preston, A. Flood, G. Waddington (Canberra, Australia)
Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)
Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)
Safinamide and Rasagiline effect on motor fluctuation, sleep quality and daytime sleepiness in Parkinson’s Disease: A validated questionnaires study

C. Liguori, A. Stefani, N. Mercuri, M. Pierantozzi (Rome, Italy)
Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)
Safinamide in Parkinson’s disease

G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)
Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease

G. Padoani, S. Novello, C. Pisanò, C. Caccia, E. Melloni, S. Vailati, C. Keywood, M. Morari (Bresso (Milan), Italy)
Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?

C. Aerts, C. Hirtz, V. Gonzalez, L. Collombier, M. De Verdal, C. Geny, M. Charif, E. Moulis, P. Fabbro-Peray, D. Deville Periere, P. Lapeyrie, G. Castelnovo, S. Lehmann (Nimes, France)
Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy

G. Vivacqua, A. Fabbrini, R. Mancinelli, D. Belvisi, G. Fabbrini, A. Suppa, A. Berardelli (Cambridge, United Kingdom)
Screening performance of abbreviated versions of the UPSIT smell test

T. Joseph, S. Auger, L. Peress, D. Rack, A. Schrag, A. Noyce (London, United Kingdom)
Screening study of COL6A3 in sporadic isolated dystonia

L.Y. Ma, T. Feng (Beijing, China)
Seasonal Fluctuation in a Chinese cohort of patients with idiopathic Restless Legs Syndrome

XY. Zhu, LY. Ni, Y. Liu, XJ. Zhang, WH. Yang, YC. Wu (Shanghai, China)
Secondary dystonic tremor after medial medullary infarction

Q. Wang, S. Wu, J.H. Dong, L.R. Jin, G. Deuschl (Shanghai, China)
Segmentation of neck muscles using ultrasound in cervical dystonia

A. Siddique, R. Cunningham, M. Silverdale, P. Harding, I. Loram, C. Kobylecki (Salford, United Kingdom)
Selection of antiparkinson drug and cognition in Japanese Parkinson Disease patients

K. Konaka, Y. Kajiyama, R. Gajanan, M. Mihara, N. Hattori, H. Mochizuki (Suita, Japan)
Selection of odorants for diagnosis of Parkinson’s disease

O. Izhboldina, N. Zhukova, V. Alifirova, A. Latypova, I. Zhukova, .Uu. Mironova, M. Nikitina, E. Kolupaeva (Tomsk, Russia)
Semi-automated segmentation and quantification of the substantia nigra depigmentation in Parkinson’s disease – a multicentre case control MRI study in 284 participants

Y. Xing, S. Schwarz, A. Martin-Bastida, L. Parkes, H. Abdul-Sapuan, S. Naidu, M. Silverdale, D. Grosset, P. Piccini, D. Burn, N. Bajaj, N. Pavese, D. Auer (Nottingham, United Kingdom)
Sensory signs and neuropathic pain in advanced Parkinson’s disease under levodopa treatment

A.E. Elia, G. Devigili, M. Damasco, L.M. Romito, P. Soliveri, S. Rinaldo, M. Falsitta, R. Eleopra (Milan, Italy)
Serum cholesterol level is associated with risk of MSA

YC. Lu, MC. Kuo, RM. Wu (Taipei, Taiwan)
Serum fractalkine levels in Parkinson’s disease: Evidence for neuroinflammation

G. Nagesh Babu, M. Gupta, V. Paliwal (Lucknow, India)
Serum glutamate is associated with the motor subtype of Parkinson’s disease

A. Latypova, I. Mironova, O. Izhboldina, I. Zhukova, N. Zhukova, E. Kolupaeva (Tomsk, Russian Federation)
Serum insulin-like growth factor-1 levels in parkinsonism or dementia disorders

K. Suzuki, S. Suzuki, Y. Ishii, T. Matsubara, H. Fujita, Y. Watanabe, M. Okamura, T. Kadowaki, H. Sakuramoto, K. Hirata (Tochigi, Japan)
Serum Leptin levels in Iranian patients with Parkinson’s disease

M. Salari, M. Etemadifar, M. Barzegar (Tehran, Islamic Republic of Iran)
Serum Uric Acid Level and Its Relationship to Non-Motor Symptomatology in Parkinson’s disease

O. Odeniyi, N. Okubadejo, O. Ojo, M. Danesi (Lagos, Nigeria)
Severe Gliosis following PPN-DBS

V. Vedam-Mai, A. Elkouzi, B. Malhotra, S. Raman, A. Yachnis, K. Foote, M. Okun (Gainesville, FL, USA)
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial

M. Schwarzschild, E. Macklin, R. Bakshi, S. Bhattacharyya,, R. Logan, A. Ascherio; on behalf of the Parkinson Study Group SURE-PD Investigators (Boston, MA, USA)
Sex Differences in Cognitive Performance in De-Novo Parkinson’s Disease

S. Banks, E. Bayram, J. Kaylegian, B. Bluett (Las Vegas, NV, USA)
Sexual Dysfunction in Women with Parkinson’s Disease

A. Hannoun, A. Deb, K. Smith (Worcester, MA, USA)
Shaky legs: The clinical spectrum and treatment of orthostatic tremor; a systematic review

A. Buijink, M. Meulepas, A. van Rootselaar (Amsterdam, Netherlands)
Siblings with a PRKRA (DYT16) Mutation and Startle Myoclonus

L. Wiblin, M. Baker, M. Lai, R. Horvath, N. Warren (Newcastle upon Tyne, United Kingdom)
Simple Programming Method in STN-DBS using directional lead

K. Kimura, H. Kishida, T. Kawasaki, K. Hamada, N. Ueda, F. Tanaka (Yokohama, Japan)
Sing to Beat Parkinson’s®: A Group Singing Intervention for People with Parkinson’s and their Carers

J. Irons, G. Hancox, D. Stewart (Derby, United Kingdom)
Single centre experiences of directional leads in Parkinson patients

U. Scheller, G. Wenzel, R. Lofredi, D. Kroneberg, K. Faust, G.H. Schneider, A.A. Kühn (Berlin, Germany)
Single limb stance test performance – Difference between tremor dominant and akinetic rigid dominant parkinson’s disease – A pilot study

S. Durairaj, A. Christina, V. Mathew, M. Gowri (Vellore, India)
Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease

A. Batla, U. Uchiyama, S. Simeoni, C. Melbourne, M. Baldwin, L. DeMin, G. Gonzales, C. Haslam, M. Pakzad, S. Islam, S. Eriksson, K. Bhatia, J. Panicker (London, United Kingdom)
SIRT1/AMPK pathway is involved in neuroprotective effects of resveratrol on MPTP-induced neuron loss

Y.J. Guo, S.Y. Dong, W.J. Zhao, Y.C. Wu (Shanghai, China)
Skin Deposition of Pathological Alpha-Synuclein in Idiopathic REM-sleep Behavior Disorder and Parkinsonism

A. Al-Qassabi, TS. Tsao, S. Dziadek, A. Racolta, T. Kremer, C. Czech, K. Taylor, W. Zago, R. Postuma (Montreal, QC, Canada)
Sleep Abnormalities in patients with Parkinson’s disease having REM sleep behaviour disorder with and without Psychosis

R. Yadav, V. Reddy, G. Kumar, L. George, A. Shashidharan, B. Kutty, P. Pal (Bangalore, India)
Sleep and other Non Motor Symptoms in Craniofacial Dystonia

S. Ray, R. Yadav, P. Pal, B. Kutty (Bangalore, India)
Sleep Disturbances and Quality of Life in People with Parkinson’s disease

U. Chotphoksap, D. Tan, S.B. Tan, EK. Tan, S. Wang, J. Chew, E. Poh, X. Chen, T.Y. Kam, K. Prakash (Singapore, Singapore)
Sleep, Fatigue and Health-related quality of life in a cohort of Parkinson disease patients

O. Ojo, N. Okubadejo, O. Odeniyi, N. Osemwegie, O. Oguntunde (Idi-araba, Nigeria)
Slowly progressive anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia over 27 years without immunosuppressive treatment

E. Schegk, I. Beiser, A. Wicki, L. Achtnichts, M. Bertschi (Aarau, Switzerland)
Smartphone App-Based Assessment of Gait in patients with Parkinson’s disease

D. Su, Z. Liu, W. Yu, H. Zhu, O. Lo, B. Manor, T. Feng, J. Zhou (Beijing, China)
Smooth muscle dysfunction in the gastrointestinal system in the 6-OHDA model of Parkinson´s Disease

P. Murillo, P. Aronsson, M. Winder, T. Carlsson (Gothenburg, Sweden)
Sniffing Parkinson’s in the masses: Volatilome analysis for Parkinson’s Disease diagnostics

M. Silverdale, D. Trivedi, E. Sinclair, Y. Xu, C. Liscio, P. Banks, T. Kunath, R. Goodacre, P. Barran (Manchester, United Kingdom)
Social interaction and Cognition in patients with Parkinson’s disease

A. Kumon, M. Sagawa, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)
Soluble TREM2 and Central and Peripheral Inflammatory Biomarkers in Parkinson’s Disease

L. Bekris, M. Khrestian, Y. Shao, H. Fernandez, J. Leverenz (Cleveland, OH, USA)
Somatosensory temporal discrimination in Parkinson’s disease, dystonia and essential tremor: Pathophysiological and clinical implications

N. Manzo, A. Conte, D. Belvisi, G. Ferrazzano, G. Fabbrini, A. Berardelli (Rome, Italy)
Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy

J.H. Lee, M.J. Lee, T.H. Kim (Yangsan-si, Gyeongsangnam-do, Republic of Korea)
Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia

C. Alcacer, M. Mendonca, A. Klaus, MA. Cenci, R. Costa (Lisbon, Portugal)
Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial

W. Meissner, A. Pavy-Le Traon, A. Foubert-Samier, M. Galitzky, B. Laurens, U. Sabatini, S. Schmidhuber, D. Winter, G. Galabova, G. Staffler, A. Schneeberger, A. Kutzelnigg, O. Rascol (Bordeaux Cedex, France)
Spectrum of movement disorders in patients of autoimmune encephalitis of non-neoplastic aetiology

D. Dash, M. Tripathi, K. Ihtisham (Delhi, India)
Spectrum of movement disorders with anti-neuronal antibodies: Case series

A. Kumar, S. Mehta, V. Lal (Chandigarh, India)
Speech and Language Therapy (SLT) for Inpatients with Parkinson’s (IwP) in a Large District General Hospital

J. Martin, A. Chatterjee (Reading, United Kingdom)
Speech in Huntington’s Disease

J.C.S. Chan, A. Vogel, J. Stout (Victoria, Australia)
Speech intelligibility and comprehensibility in Slovak patients with Parkinson’s disease

A. Kušnírová, Ľ. Mičianová, Z. Košutzká, I. Straka, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)
Speech Intelligibility in Parkinson’s disease following Intensive Voice and Articulation Treatments

G. Schulz, A. Halpern, J. Spielman, L. Ramig, I. Panzer, A. Sharpley, H. Hodges (Silver Spring, MD, USA)
Spinocerebellar Ataxia Type 2 Presenting with Chorea: Korean Cases

D. Yoo, J.Y. Lee, B. Jeon (Seoul, Republic of Korea)
Spontaneous peri-electrode edema, 7 years after subthalamic nucleus deep brain stimulation (STN-DBS) in a patient with Parkinson´s disease (PD): A case report

O. Morsi, J. Lopez, J. Jimenez, L. Fuentes, G. Valero, A.E. Baidez, E. Andreu (Murcia, Spain)
Staged bilateral Gamma Knife Thalamotomy for severe essential tremor

T. Witjas-Slucki, R. Carron, JP. Azulay, A. Eusebio, J. Regis (Marseille, France)
Start React Paradigm In Patients With Cervical Dystonia

R. Singh, S. Choudhury, A. Roy, K. Chatterjee, M. Mondal, M. Baker, S. Baker, H. Kumar (Kolkata, India)
Status of riding bicycle and reasons for cessation of cycling in patients with Parkinson disease: A Japanese single center cross-sectional survey

K. Takahashi, K. Ota, K. Seo, H. Kawasaki, K. Ikeda, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-ken, Japan)
STEEred vs RING-mode Deep Brain Stimulation for Parkinson’s disease: STEERING trial

T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam, Netherlands)
Stigma and communication in people with Parkinson’s disease (PPD)

M. Bacigalupe (La Plata, Argentina)
STN DBS – A study of frequency of gait (fog) in Parkinson’s disease

V. Rama Raju, R. Borgohain (Hyderabad, India)
STN DBS modulates cortical auditory processing in advanced Parkinson’s Disease; a MEG-study

K. Valkonen, J. Mäkelä, K. Airaksinen, J. Nurminen, R. Kivisaari, E. Pekkonen (Helsinki, Finland)
STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease

J. Li, Y. Zhang (Beijing, China)
STN-DBS causing persistent dyskinetic movements in OFF-State

J. Muellner, J. Michelis, L. Lachenmayer, K. Petermann, I. Debove (Bern, Switzerland)
STN-DBS responsive motor complication and pathological gambling in type IV SCA3

M. Kuo, C. Tai, R. Wu (New Taipei, Taiwan)
Stop Signal Reaction Time (SSRT) in Dystonia and its Correction after Botulinum Toxin Treatment

A. Roy, S. Choudhury, R. Singh, K. Chatterjee, B. Mondal, J. Ganguly, M. Baker, S. Baker, H. Kumar (Kolkata, India)
Striatal dopamine function in multiple system atrophy and progressive supranuclear palsy: A meta-analysis of imaging studies

V. Kaasinen, T. Kankare, J. Joutsa, T. Vahlberg (Turku, Finland)
Striatal dopamine transporter availability changes reflect gastrointestinal dysautonomia severity in early Parkinson’s disease

J. Hinkle, K. Perepezko, K. Mills, Z. Mari, A. Butala, T. Dawson, A. Pantelyat, L. Rosenthal, G. Pontone (Baltimore, MD, USA)
Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease

YS. Oh, DW. Ryu, JS. Kim, CH. Lyoo (Seoul, Republic of Korea)
Striatal FP-CIT SPECT findings for progressive supranuclear palsy subtypes

M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)
Striatum of the ouabain-induced pharmacological DYT12 mouse model is affected by structural and metabolic abnormalities

L. Rauschenberger, Y. Al-Zuraiqi, J. Volkmann, C.W. Ip (Wuerzburg, Germany)
Structural Abnormalities in the Cerebellar Peduncles of patients with Freezing of Gait: A Diffusion Tensor Imaging Study

K. Bharti, A. Suppa, S. Pietracupa, N. Upadhyay, C. Giannì, G. Leodori, F. Di Biaso, N. Modugno, N. Petasas, G. Grilla, A. Zampogna, A. Berardelli, P. Pantano (Rome, Italy)
Structural neural correlates of independent gait domains in Parkinson’s disease

J. Wilson, B. Galna, S. Lord, A. Yarnall, R. Lawson, G. Duncan, T. Khoo, D. Burn, L. Rochester, J.P. Taylor (Newcastle upon Tyne, United Kingdom)
Study of eye movements by video-oculography in essential tremors

M. De Verdal, A. Lozza, D. Renard, E. Thouvenot, G. Castelnovo (Nimes, France)
Study of prevalence of non-motor symptoms in typical and atypical parkinsonism as compared to age and sex matched healthy controls

N. Barad, C. Sankhla (Mumbai, India)
Study on Correlation between Serum Vitamin D Level and Cognition of Parkinson’s Disease

XY. Xu, J. Qian, XS. Huang, SY. Tian, D. Tong (Dalian, China)
Study on feasibility to develop a central nervous system (CNS) Leucine-rich repeat kinase 2 (LRRK2) PET tracer

Z. Zeng, P. Miller, T. Graham, L. Tong, D. Hesk, W. Li, E. Hostetler (West Point, PA, USA)
Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)
Studying genes involved in abnormalities of the basal ganglia and iron homeostasis using gene co-expression network analysis

M. van der Weijden, M. Tijssen, D. Verbeek (Groningen, Netherlands)
Subcortical and Cortical 123I-FP-CIT binding deficits and mild cognitive impairment in Parkinson’s disease

A. Pilotto, F. Schiano DiCola, E. Premi, V. Garibotto, A. Scalvini, R. Turrone, R. Grasso, B. Bigni, S. Gipponi, B. Paghera, MC. Rizzetti, b. Borroni, A. Padovani (Brescia, Italy)
Subjective and objective complaints of (functional) tremor: An individual approach

G. Kramer, J. Rosmalen, N. Maurits, M. Tijssen (Groningen, Netherlands)
Subjective and objective urinary dysfunction in parkinson’s disease and atypical parkinsonisms

Y. Lee, J. Kim (Seoul, Republic of Korea)
Submandibular gland is a suitable tissue for alpha synuclein pathology in Parkinson’s disease

JH. Shin, SH. Park, CW. Shin, JH. Kim, TJ. Yun, HJ. Kim, B. Jeon (Seoul, Republic of Korea)
Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson’s Disease

P. Huang, H.Y. Zhou, S.D. Chen (Shanghai, China)
Substantia nigra hyperechogenicity is similarly enlarged in Gaucher and in GBA mutation carriers

D. Arkadir, A. Zimran (Jerusalem, Israel)
Substantia nigra T1 maps for the diagnosis of Parkinson’s disease

C. Juri, L. Tapia, J. Cruz, S. Uribe, M. Andia (Santiago, Chile)
Subthalamic deep brain stimulation is safe and effective treatment for elderly patients with Parkinson’s disease

J. Youn, M. Kim, JH. Park, K.R. Cho, J.H. Ahn, JI. Lee, J.W. Cho (Seoul, Republic of Korea)
Subthalamic neuromodulation restores motor learning in Parkinson’s disease

A.L. Marcelino, A. Horn, A. Kühn, W.J. Neumann (Berlin, Germany)
Subthalamic nucleus deep brain stimulation evoked neural activity predicts clinical response to DBS

S. Xu, N. Sinclair, K. Bulluss, T. Perera, W. Lee, H. McDermott, W. Thevathasan (East Melbourne, Australia)
Subthalamic Nucleus Local Field Potential Beta Activity in Chinese Advanced PD Patients

J. Wu, J. Li, C. Xu, S. Mei, Y. Zhang (Minneapolis, MN, USA)
Subthalamic nucleus stimulation normalises effort-based decision-making in Parkinson’s disease

C. Atkinson-Clement, E. Cavazzini, A. Zénon, T. Witjas, F. Fluchère, C. Baunez, JP. Azulay, A. Eusebio (Aix-en-Provence, France)
Subthalamic theta oscillations in Parkinson’s disease

C. Oehrn, I. Weber, N. Apetz, T. Dembek, F. Jung, E. Florin, L. Timmermann (Marburg, Germany)
Suicide attempts, suicidal and death ideation in Parkinson’s disease

MM. Dumitru, A. Papari (Iasi, Romania)
Superior cerebellar peduncles atrophy of PSP on PADRE imaging; comparison with idiopathic PD

S. Kakeda, M. Miyata, T. Yoneda, S. Ide, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)
SURE-PD3 Trial Participant Features prior to Randomization

E. Macklin, A. Videnovic, C. Lungu, C. Kamp, C. Casaceli, D. Oakes, A. Ascherio, M. Schwarzschild; on behalf of the Parkinson Study Group SURE-PD3_Investigators (Boston, MA, USA)
Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

V. Kumar (Allahabad, India)
Surface Modified Solid Lipid Nanoparticles for the targeted delivery to brain: Management of HIV-1 Associated Dementia

S. Bhargava, V. Bhargava (Kanpur, India)
Surgery-, hardware – and chronic stimulation-related adverse events following subthalamic nucleus deep brain stimulation for Parkinson’s disease

B. Gonenli Kocer, E. Ozturk, S. Comoglu, M. Sorar, H. Kertmen (Ankara, Turkey)
Survival of patients with Parkinson’s disease is influenced by the mutations in the LRRK2 but not GBA gene

A. Thaler, T. Kozlovski, T. Gurevich, A. Bar Shira, M. Gana-Weisz, A. Orr-Urtreger, L. Goldstein, N. Giladi, A. Mirelman (Tel-Aviv, Israel)
Swimming in PD patients with STN-DBS: A pilot exploratory study

D. Flisar, S. Ibrulj, M. Trošt, M. Benedičič, P. Mušič, S. Korelc, K. Groleger Sršen (Ljubljana, Slovenia)
Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study

O. Fabregues, E. Tolosa, J. Ferreira, A. Lees, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)
Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)
Sydenham’s Chorea: Realities and Challenges in Sub-Saharan Africa

A. Nitcheu Woga, A. Balde, F. Sakadi, N. Tassiou, A. Bah, F. Cisse, E. Minko (Conakry, Guinea)
Symptom specified target and procedure selection for Parkinson’s disease: A case report

W. Linbin, L. Dianyou, P. Yixin, Z. chencheng, S. Bomin (Shanghai, China)
Symptomatic Isolated Tongue Tremor of Cortical Origin Due to Stroke

S. Thakolwiboon, D. Ruthirago, P. Laengvejkal, J. Kim, H. Wilms (Lubbock, TX, USA)
SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results

H. Fernandez (Cleveland, OH, USA)
Systemic variables that exacerbated physiological tremor in a general hospital in Mexico

D. Rebolledo, O. Gonzalez, J. Rebolledo, Z. Rebolledo (Toluca de Lerdo, Mexico)